APRE logo

Aprea Therapeutics, Inc.

APRE
Healthcare|Biotechnology|US
$0.52
+0.02 (+4.50%)
DCF Value
$2.14
Tangible Book / Share
$0.64
Cash / Share
$0.71

About

Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Stock Price

-56.9%(1Y)
1M
-7.3%
3M
-20.4%
6M
-47.2%
YTD
-39.3%
1Y
-59.2%
3Y
-87.3%
5Y
-99.5%

Pipeline Summary

16 total trials
13
Phase 1
10
Phase 2
1
Phase 3
0
Phase 4
Terminated: 3Completed: 10Recruiting: 1Not Yet Recruiting: 2

Active Trials (1)

Study of APR-1051 in Patients With Advanced Solid Tumors
NCT06260514Advanced Solid Tumor
Phase 1Recruiting
Enrollment: 90 participants

Key Facts

Market Cap$6.5M
Employees8 (+0% YoY)
CEOOren Gilad
IPO DateOct 3, 2019
Beta1.69
52-Week Range$0.41 – $1.49
Avg Volume238,073
ExchangeNASDAQ
Websiteaprea.com

Ownership

Float91.0%
Shares Outstanding12.6M

Recent Insider Trades

Grissinger MichaelAWARD
Jun 16, 202612,555 shares @ $0.73
Grissinger MichaelAWARD
Jun 16, 20263,135 shares
Gruia GabrielaAWARD
Jun 16, 202612,555 shares @ $0.73
Gruia GabrielaAWARD
Jun 16, 20263,135 shares
Peters RichardAWARD
Jun 16, 202612,555 shares @ $0.73

Peers

ACXPAcurx Pharmaceuticals, Inc.
$5.9M
ADILAdial Pharmaceuticals, Inc.
$13.3M
APVOAptevo Therapeutics Inc.
$1.5M
BCDABioCardia, Inc.
$12.9M
CELZCreative Medical Technology Holdings, Inc.
$1.6M
GLTODamora Therapeutics, Inc.
$34.5M
HCWBHCW Biologics Inc.
$354.6K
INABIN8bio, Inc.
$9.1M

Recent News

Aprea Therapeutics to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 5, 2026 · globenewswire.com
Aprea Therapeutics Announces Third Quarter 2026 Financial Results
Nov 4, 2026 · globenewswire.com
Aprea Therapeutics to Host Pre-ESMO Virtual Panel on the State of WEE1 Inhibition in Precision Oncology
Oct 16, 2026 · globenewswire.com
Aprea Therapeutics to Present at October Conferences
Oct 5, 2026 · globenewswire.com
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
Sep 22, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 03:55 AM